Three-Year Outcomes of the Auryon Laser Atherectomy System in Treating Infrainguinal Peripheral Arterial Disease: A...

The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc., Latham, NY) showed a high rate of freedom from target lesion revascularization (TLR) at 1-year follow-up. Long-term data for the Auryon laser are not available. In this study, we present the 3-year outcome of the Auryon SCE study on TLR in all comers at a single center. The Auryon SCE was a single-center retrospective study that evaluated the outcome of consecutive patients treated with the Auryon laser for infrainguinal arterial disease. TLR rates were obtained from medical records review. Secondary endpoints included unplanned major amputation and total mortality. Kaplan-Meier survival analysis was performed to estimate the freedom from TLR following index procedure. A total of 56 patients (65 procedures, 70 lesions) were enrolled. The mean age was 70.9 years, 48.2% diabetics, and 25% with limb ischemia. Of the 70 lesions, 31.4% had severe calcification, 38.6% were chronic total occlusions, and 48.6% were de novo disease (in-stent restenosis 29.6%). Stenting was performed in 24/70 (34.3%) lesions (11/70, 15.7% were bailout). The majority of treated lesions were femoropopliteal (90.0%). At 3 years, mortality occurred in 9/56 (16.1%) patients and major amputation 3/47 (6.4%). The probability of freedom from TLR was 65.3%. At baseline, 69.6 and 25% had severe claudication and chronic limb-threatening ischemia versus 5 and 5% at 3 years, respectively. The Auryon laser had an acceptable freedom from TLR at 3 years with sustained significant improvement in Rutherford Becker categories.